403806-35-9

Basic information

• Product Name: 1-N-BOC-4-(2-FLUOROPHENYL)-4-HYDROXYPIPERIDINE
• Synonyms: 1-BOC-4-(2-FLUOROPHENYL)-4-HYDROXYPIPERIDINE;1-N-BOC-4-(2-FLUOROPHENYL)-4-HYDROXYPIPERIDINE;4-(2-Fluoro-phenyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(2-fluorophenyl)-4-hydroxypiperidine-1-carboxylate;tert-Butyl 4-(2-fluorophenyl)-4-hydroxy-1-piperidinecarboxylate
• CAS NO: 403806-35-9
• Molecular Formula: C₁₆H₂₂FNO₃
• Molecular Weight: 295.352
• Mol File: 403806-35-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 404.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.188±0.06 g/cm3(Predicted)
• PKA: 13.52±0.20(Predicted)
• CAS DataBase Reference: 1-N-BOC-4-(2-FLUOROPHENYL)-4-HYDROXYPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-4-(2-FLUOROPHENYL)-4-HYDROXYPIPERIDINE(403806-35-9)
• EPA Substance Registry System: 1-N-BOC-4-(2-FLUOROPHENYL)-4-HYDROXYPIPERIDINE(403806-35-9)

Safety Data

• Hazardous Substances Data: 403806-35-9(Hazardous Substances Data)

Usage

Piperidine derivative

A chemical compound that is derived from piperidine, which is a heterocyclic organic compound with a nitrogen atom in the ring.

BOC protecting group

A tert-butoxycarbonyl group (-OC(CH3)3) that is used to protect the hydroxyl group from unwanted reactions, which can be removed under acidic conditions.

Fluorophenyl group

A phenyl ring (a six-carbon ring with delocalized pi electrons) that has a fluorine atom attached to it, which contributes to the compound's biological activity and stability.

Hydroxy group

A polar functional group (-OH) that can participate in hydrogen bonding and other chemical reactions, making it a useful feature in the synthesis of biologically active molecules.

Intermediate in synthesis

The compound is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds, serving as a building block for more complex molecules.

Useful building block

The presence of the fluorophenyl group makes 1-N-BOC-4-(2-Fluorophenyl)-4-hydroxypiperidine a valuable component in the construction of biologically active molecules, as it can be further modified and incorporated into various chemical structures.

Upstream product

• 1072-85-1 o-fluorobromobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 348-52-7 1-Fluoro-2-iodobenzene 

Downstream Products

• 143682-23-9 4-(2-Fluoro-phenyl)-1,2,3,6-tetrahydro-pyridine; hydrochloride 
• 143682-43-3 3-{4-[4-(2-Fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-butyl}-1H-indole 
• 1027151-29-6 1-[4-(2-Fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-4-(1H-indol-3-yl)-butan-1-one 
• 871113-19-8 4-(fluorophenyl)-4-hydroxypiperidine 
• 1274933-92-4 4-fluoro-4-(2-fluorophenyl)piperidine hydrochloride 
• 1421159-99-0 4-fluoro-4-(2-fluorophenyl)piperidine-1-sulfonamide 
• 1513866-26-6 4-(2-fluoro-phenyl)-piperidin-4-ol hydrochloride 

Relevant articles and documents

NOVEL FLUORINATED CYCLIC SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention include substituted fluorinated cyclic sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy

INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER

The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.

Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use

The subject invention provides compounds having the structure: 1 wherein,R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra;R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, orR1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH;R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb;R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl;R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12;wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring;R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl;R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, orR8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring;R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring;R11, N and R12 together form a 4-8 membered heterocyclic ring;Ra and Rb are each independently hydrogen or alkyl;m is 0, 1, 2 or 3; andk is 1, 2 or 3,or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.